Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today it has extended its Series A financing round with an additional €5.2 million subscribed by investment funds Omnes, BNP Paribas Développement, and Sham Innovati ... more
New tetrazines with improved characteristics
Germany's Federal Ministry for Economic Affairs and Energy (BMWi), the European Social Fund (ESF) and the European Union (EU) are funding the start-up venture "Tetra-Tag" with an EXIST Business Start-up Grant. Two chemists, Dr. Fabian Ehret and Dr. Vasileios Filippou, and the economist Patr ... more
Antibiotic resistance is one of the world's most serious threats to public health, forcing the use of medications that are more toxic, more expensive and not always effective. There are several causes, including over-prescription of antibiotics in both humans and in livestock.
Two engineers ... more
Dual role of protein that watches for cellular threats and repairs damage
One reason we're supposed to eat a variety of colorful fruits and vegetables is because they contain nutritious compounds called antioxidants. These molecules counteract the damage to our bodies from harmful products of normal cells called reactive oxygen species (ROS).
Now, research led by ... more
Gyros Protein Technologies AB and Cygnus Technologies announced they have signed a licensing and supply agreement.
Under the agreement, Cygnus Technologies will supply Gyros Protein Technologies with its proprietary reagents for host cell protein analysis, enabling the development of new Gy ... more
Researchers have made a breakthrough in more precisely targeting drugs to cancers. Using ultrasound and lipid drug carriers (liposomes), a multi-disciplinary team of biomedical engineers, oncologists, radiologists and anaesthetists at the University of Oxford have developed a new way to imp ... more
Collaboration in contract development and manufacturing
ProBioGen AG, a premier service and technology provider for complex therapeutic glycoproteins, andPionyr Immunotherapeutics, an immuno-oncology company which develops next generation antibody-based therapeutics that target the tumor microenvironment, today announced a second service and lic ... more
Evolva announces that as part of entering the next phase of its evolution, the current Evolva CEO Simon Waddington steps down as CEO with immediate effect. Until he will leave the company towards the end of 2018, he will support the new CEO in completing work on Evolva’s technology base. Th ... more
Last month alone, 23 percent of Americans took two or more prescription drugs, according to one CDC estimate, and 39 percent over age 65 take five or more, a number that's increased three-fold in the last several decades. And if that isn't surprising enough, try this one: in many cases, doc ... more
CO.DON AG has signed a letter of intent (LOI) with Xintela AB, Lund (Sweden), by which the two companies have agreed to start negotiations regarding the establishment of a joint venture for the development and commercialization of stem cell based options for the treatment of cartilage disor ... more